Q4 2025 Zymeworks Inc Earnings Call Transcript
Key Points
- Zymeworks Inc (ZYME) reported positive results from the Phase 3 Horizon-GA01 trial, showing significant survival benefits for HER2-positive GEA patients.
- The company has secured a $250 million royalty-backed note financing with Royalty Pharma, providing non-dilutive capital for strategic investments.
- Zymeworks Inc (ZYME) is eligible for up to $1.5 billion in milestone payments from partnerships, indicating strong future revenue potential.
- The company has a robust pipeline with ongoing studies in multiple cancer types, including breast cancer and biliary tract cancer.
- Zymeworks Inc (ZYME) has a strong cash position, with resources expected to fund operations beyond 2028, providing financial stability.
- The company reported a net loss of $81.1 million for 2025, although this was an improvement from the previous year.
- Operating expenses remain high, with $198.5 million reported for 2025, despite a decrease from 2024.
- There is uncertainty regarding the timing and outcome of regulatory approvals for zanidatamab in various regions.
- The competitive landscape for ADCs and HER2-targeted therapies is crowded, posing challenges for market differentiation.
- Zymeworks Inc (ZYME) faces risks associated with clinical trial progress and potential delays in achieving key milestones.
Thank you for standing by. This is the conference operator. Welcome to the Zymeworks fourth quarter 2025 results conference call and webcast. (Operator Instructions) I would now like to turn the conference over to Shrinal Inamdar, Vice President of Investor Relations. Shrinal, please go ahead.
Thank you, operator, and good morning, everyone. Thank you for joining our fourth quarter 2025, results conference call. As usual, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary.
Forward-looking statements are based upon our current expectations and various assumptions and are subject to risks and uncertainties, including those associated with the company in our industry and at our stage of development a discussion of these risks and uncertainties and uncertainties for you to the latest SEC filings as found on our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
